Susannah Gray - 23 May 2022 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Reporting relationship: Director
Issuer ticker: FDMT
Reported as of: 23 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 May 2022, 19:01:23 UTC
Prior SEC filing: 29 Mar 2022
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ August J. Moretti, Attorney-in-Fact for Susannah Gray

Key filing fact

Susannah Gray filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 25 May 2022.

Key facts

This page summarizes Susannah Gray's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 May 2022, 19:01.

Change

Previous filing in this sequence was filed on 29 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FDMT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +22,500
Change %
Price: $0.000000
Shares after: 22,500
Date: 23 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,500
Exercise price: $7.77
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

Footnote F2

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).